Fosfomycin最新文獻回顧及臨床使用建議

10.6666/ClinMed.201807_82(1).0074

陳夙容

弗斯黴素(fosfomycin) ； 多重抗藥性細菌(multidrug-resistant bacteria, MDR bacteria) ； 抗生素治療(antimicrobial therapy) ； 泌尿道感染(urinary tract infection)

臨床醫學月刊

82卷1期（2018 / 07 / 27）

408 - 420

繁體中文

由於多重抗藥性(multidrug-resistant, MDR)細菌問題日益嚴重以及新型抗微生物製劑研發腳步逐漸趨緩，當醫師在面臨棘手的抗藥性細菌感染時，又轉而開始嘗試近年相對少用的老藥如polymyxins, tetracyclines和aminoglycosides。然而隨著這些藥物愈來愈被廣泛使用，抗藥性問題也隨之上升。口服fosfomycin在以往多被使用來治療膀胱炎等非複雜型泌尿道感染(non-complicated urinary tract infection)或當作泌尿外科手術前的預防性抗生素，由於其對革蘭氏陽性及陰性抗藥性菌均保有一定的敏感性，所以在近年來又重新引起注意。以下我們將針對fosfomycin的作用機轉、藥理學特性、抗生素敏感性試驗、治療過程中產生的抗藥性問題、與其它抗生素的協同作用及臨床治療的適應症及副作用等議題做最新的文獻回顧。

1. Anderson, GG,Kenney, TF,Macleod, DL(2013).Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination.Pathog Dis,67,39-45.
2. Barahona-Garrido, J,Quinonez, NF,Cerda-Contreras, E(2013).Fosfomycincontaining second-line treatment for Helicobacter pylori infection.Am J Gastroenterol,108,858-859.
3. Barry, AL,Brown, SD(1995).Antibacterial spectrum of fosfomycin trometamol.J Antimicrob Chemother,35,228-230.
4. Boyanova, L,Davidkov, L,Gergova, G(2014).Helicobacter pylori susceptibility to fosfomycin, rifampin, and 5 usual antibiotics for H. pylori eradication.Diagn Microbiol Infect Dis,79,358-361.
5. Cai, Y,Fan, Y,Wang, R(2009).Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model.J Antimicrob Chemother,64,563-566.
6. Careddu, P,Borzani, M,Scotti, L(1987).Treatment of lower urinary tractinfections in children: single dose fosfomycin trometamol versus pipemidic acid.Chemioterapia,6,290-294.
7. Corvec, S,Furustrand, Tafin,Betrisey, B(2013).Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-beta-lactamaseproducing Escherichia coli in a foreignbody infection model.Antimicrob Agents Chemother,57,1421-1427.
8. De, Smet, KA,Kempsell, KE,Gallagher, A(1999).Alteration of a single amino acid residue reverses fosfomycin resistance of recombinant MurA from Mycobacterium tuberculosis.Microbiology,145,3177-3184.
9. Dengler, V,Meier, PS,Heusser, R(2011).Induction kinetics of the Staphylococcusaureus cell wall stress stimulon in response to different cell wall active antibiotics.BMC Microbiol,11,16.
10. Descourouez, JL,Jorgenson, MR,Wergin, JE(2013).Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents.Antimicrob Agents Chemother,57,1518-1520.
11. Falagas, ME,Giannopoulou, KP,Kokolakis, GN(2008).Fosfomycin: use beyond urinary tract and gastrointestinal infections.Clin Infect Dis,46,1069-1077.
12. Falagas, ME,Kastoris, AC,Kapaskelis, AM(2010).Fosfomycin for the treatment of multidrug-resistant, including extendedspectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.Lancet Infect Dis,10,43-50.
13. Falagas, ME,Kastoris, AC,Karageorgopoulos, DE(2009).Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.Int J Antimicrob Agents,34,111-120.
14. Falagas, ME,Vouloumanou, EK,Samonis, G(2016).Fosfomycin.Clin Microbiol Rev,29,321-347.
15. Falagas, ME,Vouloumanou, EK,Togias, AG(2010).Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials.J Antimicrob Chemother,65,1862-1877.
16. Florent, A,Chichmanian, RM,Cua, E(2011).Adverse events associated with intravenous fosfomycin.Int J Antimicrob Agents,37,82-83.
17. Fukuyama, M,Furuhata, K,Oonaka, K(2000).Antibacterial activity of fosfomycin against the causative bacteria isolated from bacterial enteritis.Jpn J Antibiot,53,522-531.
18. Guggenbichler, JP,Bonatti, H,Rottensteiner, F(1989).Resistance of staphylococci to intracellular killing by macrophages--a new pathophysiologic concept of acute hematogenous osteomyelitis in childhood and its therapeutic consequences.Padiatr Padol,24,21-32.
19. Hajdu, S,Lassnigg, A,Graninger, W(2009).Effects of vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms.J Orthop Res,27,1361-1365.
20. Hirt, SW,Alken, A,Muller, H(1990).Perioperative preventive antibiotic treatment with fosfomycin in heart surgery: serum kinetics in extracorporeal circulation and determination of concentration in heart valve tissue.Z Kardiol,79,615-620.
21. Hirzel, C,Guilarte, YN,Hirzberger, L(2015).In vitro susceptibility of Aerococcus urinae isolates to antibiotics used for uncomplicated urinary tract infection.J Infect,71,395-397.
22. Joko, T,Shiraishi, A,Kobayashi, T(2017).Mechanism of Proliferation of Cultured Human Corneal Endothelial Cells.Cornea,36(Suppl 1),S41-S45.
23. Joukhadar, C,Klein, N,Dittrich, P(2003).Target site penetration of fosfomycin in critically ill patients.J Antimicrob Chemother,51,1247-1252.
24. Lee, H,Kim, H,Seo, YH(2017).In vitro activity of tigecycline alone and antimicrobial combinations against clinical Neisseria gonorrhoeae isolates.Diagn Microbiol Infect Dis,87,160-162.
25. Lepe, JA,Torres, MJ,Smani, Y(2014).In vitro and intracellular activities of fosfomycin against clinical strains of Listeria monocytogenes.Int J Antimicrob Agents,43,135-139.
26. Lista, F,Redondo, C,Meilan, E(2014).Efficacy and safety of fosfomycin-trometamol in the prophylaxis for transrectal prostate biopsy. Prospective randomized comparison with ciprofloxacin.Actas Urol Esp,38,391-396.
27. Mazzei, T,Cassetta, MI,Fallani, S(2006).Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections.Int J Antimicrob Agents,28,S35-S41.
28. Michalopoulos, AS,Livaditis, IG,Gougoutas, V(2011).The revival of fosfomycin.Int J Infect Dis,15,e732-e739.
29. Mihailescu, R,Furustrand, Tafin U,Corvec, S(2014).High activity of Fosfomycin and Rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model.Antimicrob Agents Chemother,58,2547-2553.
30. Montiel, EE,Ruiz-Ruano, FJ,Cabrero, J(2015).Intragenomic distribution of RTE retroelements suggests intrachromosomal movement.Chromosome Res,23,211-223.
31. Nakamura, T,Hashimoto, I,Sawada, Y(1985).Clinical studies on fosfomycin sodium following intravenous administration (tissue concentration and clinical efficacy).Jpn J Antibiot,38,2057-2067.
32. Nau, R,Zysk, G,Reinert, RR(1995).Activity of fosfomycin in a rabbit model of experimental pneumococcal meningitis.J Antimicrob Chemother,36,997-1004.
33. Neuner, EA,Sekeres, J,Hall, GS(2012).Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.Antimicrob Agents Chemother,56,5744-5748.
34. Okada, N,Nishio, M,Danbara, H(2003).Intracellular activity of fosfomycin against two distinct enteropathogenic bacteria, Salmonella enterica and Listeria monocytogenes, alive inside host cells.Chemotherapy,49,49-55.
35. Oliva, A,Furustrand, Tafin U,Maiolo, EM(2014).Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model.Antimicrob Agents Chemother,58,1284-1293.
36. Ongun, S,Aslan, G,Avkan-Oguz, V(2012).The effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasoundguided biopsy of the prostate.Urol Int,89,439-444.
37. Oteo, J,Orden, B,Bautista, V(2009).CTXM-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.J Antimicrob Chemother,64,712-717.
38. Patel, SS,Balfour, JA,Bryson, HM(1997).Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.Drugs,53,637-656.
39. Petsch, M,Mayer-Helm,Sauermann, R(2005).Determination of fosfomycin in pus by capillary zone electrophoresis.J Chromatogr A,1081,55-59.
40. Pogue, JM,Marchaim, D,Abreu-Lanfranco, O(2008).Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycinresistant Enterococcus, Detroit, 2008-10.J Antibiot,66,625-627.
41. Rhodes, NJ,Gardiner, BJ,Neely, MN(2015).Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis.J Antimicrob Chemother,70,2068-2073.
42. Rosso-Fernandez, C,Sojo-Dorado, J,Barriga, A(2015).Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.BMJ Open,5,e007363.
43. Roussos, N,Karageorgopoulos, DE,Samonis, G(2009).Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections.Int J Antimicrob Agents,34,506-515.
44. Samonis, G,Maraki, S,Rafailidis, PI(2010).Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials.Future Microbiol,5,961-970.
45. Sauermann, R,Karch, R,Langenberger, H(2005).Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles.Antimicrob Agents Chemother,49,4448-4454.
46. Schintler, MV,Traunmuller, F,Metzler, J(2009).High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection.J Antimicrob Chemother,64,574-578.
47. Senol, S,Tasbakan, M,Pullukcu, H(2010).Carbapenem versus fosfomycin tromethanol in the treatment of extendedspectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.J Chemother,22,355-357.
48. Shaw, E,Miro, JM,Puig-Asensio, M(2015).Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial.BMJ Open,5,e006723.
49. Shi, J,Mao, NF,Wang, L(2014).Efficacy of combined vancomycin and fosfomycin against methicillin-resistant Staphylococcus aureus in biofilms in vivo.PLoS,9,e113133.
50. Stock, I,Wiedemann, B(1998).Identification and natural antibiotic susceptibility of Morganella morganii.Diagn Microbiol Infect Dis,30,153-165.
51. Stock, I,Wiedemann, B(1999).Natural antibiotic susceptibility of Escherichia coli, Shigella, E. vulneris, and E. hermannii strains.Diagn Microbiol Infect Dis,33,187-199.
52. Takahata, S,Ida, T,Hiraishi, T(2010).Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli.Int J Antimicrob Agents,35,333-337.
53. Tang, HJ,Chen, CC,Zhang, CC(2013).In vitro efficacy of fosfomycinbased combinations against clinical vancomycin-resistant Enterococcus isolates.Diagn Microbiol Infect Dis,77,254-257.
54. Trautmann, M,Meincke, C,Vogt, K(1992).Intracellular bactericidal activity of fosfomycin against staphylococci: a comparison with other antibiotics.Infection,20,350-354.
55. Yu, XH,Song, XJ,Cai, Y(2010).In vitro activity of two old antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus.J Antibiot,63,657-659.